Cytokines are known to be a group of growing small proteins that are majorly responsible for the transmission of signals and communication between hematopoietic cells, the cells of the human immune system, and other types of cells. Cytokines play a dominant role in different types of disorders and in perpetuating the inflammation-related disorders. The production of cytokines is a natural process inside the body of a human being against any foreign invasion or due to some pathogenic state to maintain the homeostasis. Cytokines respond in two ways; in some cases, the production and development of cytokines as a therapeutic discovery or intervention will enhance the treatment process and support the reaction given by the body against any pathogenic activity, and in some cases, overproduction of these cytokines responds in the opposite way and behaves as antagonists toward a typical therapeutic drug and its treatment. Overall, 41 articles were reviewed, and it was found that cytokines have proved to be a therapeutic approach among various diseases and can be utilized as a good candidate or a better choice for cancer therapeutics in future development.
Get full access to this article
View all access options for this article.
References
1.
AlbertsB, JohnsonA, LewisJ, et al.Helper T Cells and Lymphocyte Activation. Garland Science: New York; 2002.
2.
Al-QahtaniAA, AlhamlanFS, Al-QahtaniAA. Pro-Inflammatory and anti-inflammatory interleukins in infectious diseases: A comprehensive review. Trop Med Infect Dis, 2024; 9(1); doi: 10.3390/TROPICALMED9010013
3.
ArunKV, TalwarA, KumarTSS. T-Helper cells in the etiopathogenesis of periodontal disease: A mini review. J Indian Soc Periodontol, 2011; 15(1):4–10; doi: 10.4103/0972-124X.82255
4.
BerraondoP, SanmamedMF, OchoaMC, et al.Cytokines in clinical cancer immunotherapy. Br J Cancer, 2018; 120(1):6–15; doi: 10.1038/s41416-018-0328-y
5.
CampanatiA, MaraniA, MartinaE, et al.Psoriasis as an immune-mediated and inflammatory systemic disease: From pathophysiology to novel therapeutic approaches. Biomedicines, 2021; 9(11); doi: 10.3390/BIOMEDICINES9111511
6.
CannonJG. Inflammatory cytokines in nonpathological states. News Physiol Sci, 2000; 15(6):298–303; doi: 10.1152/PHYSIOLOGYONLINE.2000.15.6.298
7.
ChenL, DengH, CuiH, et al.Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 2018; 9(6):7204–7218; doi: 10.18632/ONCOTARGET.23208
8.
CiccheseJM, EvansS, HultC, et al.Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology. Immunol Rev, 2018; 285(1):147–167; doi: 10.1111/IMR.12671
9.
ConlonKC, MiljkovicMD, WaldmannTA. Cytokines in the treatment of cancer. J Interferon Cytokine Res, 2019; 39(1):6–21; doi: 10.1089/JIR.2018.0019
DonnellyRP, YoungHA, RosenbergAS. An overview of cytokines and cytokine antagonists as therapeutic agents. Ann N Y Acad Sci, 2009; 1182:1–13; doi: 10.1111/J.1749-6632.2009.05382.X
12.
EvangelatosG, BamiasG, KitasGD, et al.The second decade of anti-TNF-a therapy in clinical practice: New lessons and future directions in the COVID-19 era. Rheumatol Int, 2022; 42(9):1493–1511; doi: 10.1007/S00296-022-05136-X
13.
FeldmannM. Many cytokines are very useful therapeutic targets in disease. J Clin Invest, 2008; 118(11):3533–3536; doi: 10.1172/JCI37346
14.
FeldmannM, MainiSR. Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics. Immunol Rev, 2008; 223(1):7–19; doi: 10.1111/J.1600-065X.2008.00626.X
15.
GarebB, OttenAT, FrijlinkHW, et al.Review: Local tumor necrosis factor-α inhibition in inflammatory bowel disease. Pharmaceutics, 2020; 12(6):1–31; doi: 10.3390/PHARMACEUTICS12060539
16.
GieseckRL, WilsonMS, WynnTA. Type 2 Immunity in tissue repair and fibrosis. Nat Rev Immunol, 2017; 18(1):62–76; doi: 10.1038/nri.2017.90
17.
GuoN and Lv LuL. Mechanistic insights into the role of probiotics in modulating immune cells in Ulcerative colitis. Immun Inflamm Dis, 2023; 11(10):e1045; doi: 10.1002/IID3.1045
18.
GuptaRC, LallR, SrivastavaA, et al.Hyaluronic acid: Molecular mechanisms and therapeutic trajectory. Front Vet Sci, 2019; 6(JUN):192; doi: 10.3389/FVETS.2019.00192
19.
HabibN, PashaMA, TangDD. Current understanding of asthma pathogenesis and biomarkers. Cells, 2022; 11(17); doi: 10.3390/CELLS11172764
20.
HanY, LiuD, LiL. PD-1/PD-L1 pathway: Current researches in cancer. Am J Cancer Res, 2020; 10(3):727–742.
21.
IyerSS, ChengG. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol, 2012; 32(1):23–63.
22.
JangDI, LeeAH, ShinHY, et al.The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci, 2021; 22(5):1–16; doi: 10.3390/IJMS22052719
23.
JarczakD, KlugeS, NierhausA. Sepsis—pathophysiology and therapeutic concepts. Front Med (Lausanne), 2021; 8:628302; doi: 10.3389/FMED.2021.628302
24.
JuG. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci U S A, 1994; 91(4):1198–1205; doi: 10.1073/PNAS.91.4.1198
25.
KanyS, VollrathJT, ReljaB. Cytokines in inflammatory disease. Int J Mol Sci, 2019; 20(23); doi: 10.3390/IJMS20236008
KruegerE. Cytokines: Roles and Therapeutic Implications. Novapublishers; 2020.
28.
KumarS, JeongY, AshrafMU, et al.Dendritic cell-mediated Th2 immunity and immune disorders. Int J Mol Sci, 2019; 20(9); doi: 10.3390/IJMS20092159
29.
KuzmichNN, SivakKV, ChubarevVN, et al.TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines (Basel), 2017; 5(4):34; doi: 10.3390/VACCINES5040034
30.
LambrechtBN, HammadH, FahyJV. The cytokines of asthma. Immunity, 2019; 50(4):975–991; doi: 10.1016/J.IMMUNI.2019.03.018
31.
LiM, YouR, SuY, et al.Characteristic analysis of adverse reactions of five anti-TNFɑ agents: A descriptive analysis from WHO-VigiAccess. Front Pharmacol, 2023; 14:1169327; doi: 10.3389/FPHAR.2023.1169327/FULL
32.
Lopez-CastejonG, BroughD. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev, 2011; 22(4):189–195; doi: 10.1016/J.CYTOGFR.2011.10.001
33.
LubbertsE and Van den BergWB. Cytokines in the Pathogenesis of Rheumatoid Arthritis and Collagen-Induced Arthritis. Landes Bioscience: Austin (TX); 2013.
34.
LuoP, WangP, XuJ, et al.Immunomodulatory role of T helper cells in rheumatoid arthritis: A comprehensive research review. Bone Joint Res, 2022; 11(7):426–438; doi: 10.1302/2046-3758.117.BJR-2021-0594.R1
35.
McGonagleD, SharifK, O’ReganA, et al.The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev, 2020; 19(6):102537; doi: 10.1016/J.AUTREV.2020.102537
36.
MillerCH, MaherSG, YoungHA. Clinical use of interferon-gamma. Ann N Y Acad Sci, 2009; 1182:69–79; doi: 10.1111/J.1749-6632.2009.05069.X
37.
Mire-SluisAR. Cytokines: From technology to therapeutics. Trends Biotechnol, 1999; 17(8):319–325; doi: 10.1016/S0167-7799(99)01330-X
38.
MoránGAG, Parra-MedinaR, CardonaAG, et al.Cytokines, Chemokines and Growth Factors. El Rosario University Press: Bogota (Colombia); 2013.
39.
NahtaR, HungMC, EstevaFJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res, 2004; 64(7):2343–2346; doi: 10.1158/0008-5472.CAN-03-3856
40.
NiW, YangX, YangD, et al.Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19. Crit Care, 2020; 24(1):422–410; doi: 10.1186/S13054-020-03120-0
41.
NirenjenS, NarayananJ, TamilanbanT, et al.Exploring the contribution of pro-inflammatory cytokines to impaired wound healing in diabetes. Front Immunol, 2023; 14:1216321; doi: 10.3389/FIMMU.2023.1216321
42.
PanL, LuMP, WangJH, et al.Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr, 2020; 16(1):19–30; doi: 10.1007/S12519-019-00229-3
PcT. Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Des, 2003; 9(14):1095–1126; doi: 10.2174/1381612033454991
45.
PelaiaC, HefflerE, CrimiC, et al.Interleukins 4 and 13 in Asthma: Key pathophysiologic cytokines and druggable molecular targets. Front Pharmacol, 2022; 13:851940; doi: 10.3389/FPHAR.2022.851940
46.
PopeRM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol, 2002; 2(7):527–535; doi: 10.1038/nri846
47.
Rafael-VidalC, PérezN, AltabásI, et al.Blocking IL-17: A promising strategy in the treatment of systemic rheumatic diseases. Int J Mol Sci, 2020; 21(19):1–14; doi: 10.3390/IJMS21197100
48.
RokniM, HamblinMR, RezaeiN. Cytokines and COVID-19: Friends or foes? Hum Vaccin Immunother, 2020; 16(10):2363–2365; doi: 10.1080/21645515.2020.1799669
49.
Sanchez-MuñozF, Dominguez-LopezA, Yamamoto-FurushoJK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol, 2008; 14(27):4280–4288; doi: 10.3748/WJG.14.4280
50.
SanjabiS, ZenewiczLA, KamanakaM, et al.Anti- and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol, 2009; 9(4):447–453; doi: 10.1016/J.COPH.2009.04.008
51.
SchaperF, Rose-JohnS. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev, 2015; 26(5):475–487; doi: 10.1016/J.CYTOGFR.2015.07.004
52.
StrzelecM, DetkaJ, MieszczakP, et al.Immunomodulation—A general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol, 2023; 14:1127704; doi: 10.3389/FIMMU.2023.1127704/BIBTEX
53.
TaniguchiT. Aimez-Vous Brahms? A story capriccioso from the discovery of a cytokine family and its regulators. Nat Immunol, 2009; 10(5):447–449.
54.
TayalV, KalraBS. Cytokines and anti-cytokines as therapeutics–an update. Eur J Pharmacol, 2008; 579(1–3):1–12; doi: 10.1016/J.EJPHAR.2007.10.049
55.
VilcekJ, FeldmannM. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci, 2004; 25(4):201–209; doi: 10.1016/J.TIPS.2004.02.011
56.
WangX, LinY. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin, 2008; 29(11):1275–1288; doi: 10.1111/J.1745-7254.2008.00889.X
57.
WojdasiewiczP, PoniatowskiŁA, SzukiewiczD. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm, 2014; 2014:561459; doi: 10.1155/2014/561459
58.
YilmazÖ, LeeKL. The inflammasome and danger molecule signaling: At the crossroads of inflammation and pathogen persistence in the oral cavity. Periodontol 2000, 2015; 69(1):83–95; doi: 10.1111/PRD.12084
59.
ZettlitzKA. Engineered antibodies for the therapy of cancer and inflammatory diseases. 2010.
60.
ZhangJM, AnJ. Cytokines, Inflammation and pain. Int Anesthesiol Clin, 2007; 45(2):27–37; doi: 10.1097/AIA.0B013E318034194E
61.
ZhangW, ZhaoY, ZhangF, et al.The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol, 2020; 214:108393; doi: 10.1016/J.CLIM.2020.108393
62.
ZhouX, ChenY, CuiL, et al.Advances in the pathogenesis of psoriasis: From keratinocyte perspective. Cell Death Dis, 2022; 13(1):81; doi: 10.1038/S41419-022-04523-3
63.
ZhuX, ZhuJ. CD4 T helper cell subsets and related human immunological disorders. Int J Mol Sci, 2020; 21(21):1–26; doi: 10.3390/IJMS21218011
